Articles on drug prices

Displaying all articles

The PBAC must make tough decisions about which cancer drugs to subsidise. Eric Gaillard/Reuters

New cancer drugs are very expensive - here’s how we work out value for our money

Most of us would agree that cancer drugs should be listed on the PBS, no matter how dear. But our health system can't afford all of them. How then are decisions about which drugs to subsidise made?
Trade minister Andrew Robb attends negotiations for the Trans Pacific Partnership in Sydney last year. Dan Himbrechts/AAP Image

How the battle over biologics helped stall the Trans Pacific Partnership

Over the next few weeks, the trade minister will be under intense pressure to renege on the government’s commitment to reject anything in the Trans Pacific Partnership that could undermine the PBS.
A group of oncologists have called on cancer patients to challenge the high prices charged by pharmaceutical companies for new cancer drugs. ep_jhu/Flickr

If we don’t talk about value, cancer drugs will become terminal for health systems

Hope, fear, and desperation, along with the unique characteristics of the cancer drug market, create a “perfect storm” that continues to drive up prices for cancer drugs.

Top contributors